Free Daily Technical Summary Reports on LivaNova and Three Other Medical Equipment Stocks

Stock Research Monitor: GMED, INSP, and NSPR

LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on LIVN sign up now at www.wallstequities.com/registration. WallStEquities.com monitors four Medical Appliances and Equipment stocks, namely: Globus Medical Inc. (NYSE: GMED), Inspire Medical Systems Inc. (NYSE: INSP), InspireMD Inc. (NYSE AMER: NSPR), and LivaNova PLC (NASDAQ: LIVN). These companies belong to the healthcare sector, which specializes in products and services related to health and medical care. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Globus Medical

Audubon, Pennsylvania headquartered Globus Medical Inc.’s shares recorded a trading volume of 636,640 shares last Friday. The stock finished the trading session 0.72% higher at $55.95. The Company’s shares have gained 12.69% in the last month, 15.62% over the previous three months, and 77.45% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.15% and 35.70%, respectively. Furthermore, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have a Relative Strength Index (RSI) of 74.83.

On May 21st, 2018, Globus Medical announced the appointment of Daniel Gregoris to Vice President of Sales for its emerging Orthopedic Trauma division. Gregoris will be responsible for leading the growth and expansion of the Company’s direct Trauma sales force and the development and execution of all domestic sales strategies within the Trauma business unit.

On June 01st, 2018, research firm Cantor Fitzgerald initiated an ‘Overweight’ rating on the Company’s stock. Get the full research report on GMED for free by clicking below at:

www.wallstequities.com/registration/?symbol=GMED

Inspire Medical Systems

On Friday, Maple Grove, Minnesota headquartered Inspire Medical Systems Inc.’s stock ended the session 2.80% higher at $30.84. A total volume of 274,799 shares was traded. Shares of the Company, which focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea, are trading 5.56% above its 50-day moving average.

On May 29th, 2018, research firm Wells Fargo initiated an ‘Outperform’ rating on the Company’s stock.

On May 30th, 2018, Inspire Medical Systems announced that its management team will be presenting at the Goldman Sachs 39th Annual Global Healthcare Conference on June 12th, 2018 at the Terranea Resort in Rancho Palos Verdes, California. The Company is scheduled to present at 10:00 a.m. PT. The free technical report on INSP can be accessed at:

www.wallstequities.com/registration/?symbol=INSP

InspireMD

Tel Aviv, Israel headquartered InspireMD Inc.’s stock ended the day flat at $1.19 with a total trading volume of 401,069 shares. The stock is trading 8.83% below its 50-day moving average. Shares of the Company, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases, have an RSI of 49.89.

On May 16th, 2018, InspireMD announced that it has received regulatory approval for the CGuard™ Embolic Prevention System and MGuard Prime™ from the Ministry of Health in Ecuador. Both of these devices utilize the Company’s patented MicroNet™ technology. Sign up for free on Wall St. Equities and claim the latest report on NSPR at:

www.wallstequities.com/registration/?symbol=NSPR

LivaNova

Shares in London, the UK headquartered LivaNova PLC recorded a trading volume of 832,162 shares, which was above their three months average volume of 436,230 shares. The stock ended Friday’s session 0.85% higher at $94.85. The Company’s shares have gained 13.84% in the last month, 8.17% over the previous three months, and 64.27% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.54% and 18.33%, respectively. Furthermore, shares of LivaNova, which designs, develops, manufactures, and sells therapeutic solutions worldwide, have an RSI of 73.63.

On May 31st, 2018, research firm Needham reiterated its ‘Buy’ rating on the Company’s stock with an increase of the target price from $102 a share to $106 a share.

On May 31st, 2018, LivaNova announced that CEO Damien McDonald and CFO Thad Huston will participate in the Jefferies 2018 Global Healthcare Conference on June 06th, 2018, at 4:00 p.m. EDT in New York. On June 13th, 2018, McDonald will participate in the Goldman Sachs 39th Annual Global Healthcare Conference at 3:20 p.m. PDT in Rancho Palos Verdes, California. See the free research coverage on LIVN at:

www.wallstequities.com/registration/?symbol=LIVN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501643